首页> 外文期刊>American journal of medical genetics, Part A >Chromosomal microarray analysis (CMA) detects a large X chromosome deletion including FMR1, FMR2, and IDS in a female patient with mental retardation.
【24h】

Chromosomal microarray analysis (CMA) detects a large X chromosome deletion including FMR1, FMR2, and IDS in a female patient with mental retardation.

机译:染色体微阵列分析(CMA)在患有智力障碍的女性患者中检测到大的X染色体缺失,包括FMR1,FMR2和IDS。

获取原文
获取原文并翻译 | 示例
           

摘要

Chromosomal microarray analysis (CMA) by array-based comparative genomic hybridization (CGH) is a new clinical test for the detection of well-characterized genomic disorders caused by chromosomal deletions and duplications that result in gene copy number variation (CNV). This powerful assay detects an abnormality in approximately 7-9% of patients with various clinical phenotypes, including mental retardation. We report here on the results found in a 6-year-old girl with mildly dysmorphic facies, obesity, and marked developmental delay. CMA was requested and showed a heterozygous loss in copy number with clones derived from the genomic region cytogenetically defined as Xq27.3-Xq28. This loss was not cytogenetically visible but was seen on FISH analysis with clones from the region. Further studies confirmed a loss of one copy each of the FMR1, FMR2, and IDS genes (which are mutated in Fragile X syndrome, FRAXE syndrome, and Hunter syndrome, respectively). Skewed X-inactivation has been previously reported in girls with deletions in this region and can lead to a combined Fragile X/Hunter syndrome phenotype in affected females. X-inactivation and iduronate 2-sulfatase (IDS) enzyme activity were therefore examined. X-inactivation was found to be random in the child's peripheral leukocytes, and IDS enzyme activity was approximately half of the normal value. This case demonstrates the utility of CMA both for detecting a submicroscopic chromosomal deletion and for suggesting further testing that could possibly lead to therapeutic options for patients with developmental delay.
机译:通过基于阵列的比较基因组杂交(CGH)进行的染色体微阵列分析(CMA)是一项新的临床测试,用于检测由染色体缺失和重复导致基因拷贝数变异(CNV)导致的特征明确的基因组疾病。这项功能强大的检测方法可在大约7-9%的患有各种临床表型(包括智力低下)的患者中检测到异常。我们在这里报告在一个6岁的女孩中发现的结果,该女孩患有轻度畸形的面部,肥胖症和明显的发育延迟。请求CMA并显示其拷贝数杂合丢失,这些克隆的杂合子丢失源于细胞遗传学定义为Xq27.3-Xq28的基因组区域。这种损失在细胞遗传学上不是可见的,但是在来自该区域的克隆的FISH分析中可以看到。进一步的研究证实,FMR1,FMR2和IDS基因(分别在脆性X综合征,FRAXE综合征和Hunter综合征中发生突变)各自丢失一个拷贝。先前曾报道过该区域缺失的女孩偏斜的X型失活,并且会在受影响的女性中导致脆性X /亨特综合征综合表型。因此,检查了X-失活和二聚异氰酸酯(IDS)的酶活性。发现X灭活在儿童外周血白细胞中是随机的,IDS酶的活性约为正常值的一半。这种情况表明,CMA既可用于检测亚显微染色体缺失,又可用于建议进一步测试,从而可能为发育迟缓的患者提供治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号